Business Description
LSL Pharma Group Inc
NAICS : 325412
SIC : 3741
ISIN : CA50190N1042
Share Class Description:
TSXV:LSL: Class ACompare
Compare
Traded in other countries / regions
LSL.Canada IPO Date
2023-03-01Description
LSL Pharma Group Inc integrated pharmaceutical company specializing in the development, manufacture and distribution of high-quality natural health products and dietary supplements in solid dosage forms as well as high quality sterile ophthalmic pharmaceutical products.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 1.42 | |||||
| Debt-to-EBITDA | -5.59 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 96.94 | |||||
| 9-Day RSI | 87.36 | |||||
| 14-Day RSI | 77.18 | |||||
| 6-1 Month Momentum % | -5.56 | |||||
| 12-1 Month Momentum % | -22.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.42 | |||||
| Quick Ratio | 0.15 | |||||
| Days Inventory | 422.73 | |||||
| Days Sales Outstanding | 140.86 | |||||
| Days Payable | 536.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 0.34 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 25.5 | |||||
| Operating Margin % | -67.11 | |||||
| Net Margin % | -85.06 | |||||
| FCF Margin % | -63.26 | |||||
| ROE % | -53.96 | |||||
| ROA % | -17.53 | |||||
| ROIC % | -10.92 | |||||
| ROC (Joel Greenblatt) % | -21.85 | |||||
| ROCE % | -23.57 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.09 | |||||
| PB Ratio | 4.24 | |||||
| Price-to-Tangible-Book | 50 | |||||
| EV-to-EBIT | -22.52 | |||||
| EV-to-EBITDA | -28.29 | |||||
| EV-to-Revenue | 15.46 | |||||
| EV-to-FCF | -24.43 | |||||
| Earnings Yield (Greenblatt) % | -4.44 | |||||
| FCF Yield % | -5.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LSL Pharma Group Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 4.546 | ||
| EPS (TTM) (C$) | -0.05 | ||
| Beta | 0 | ||
| Volatility % | 43.12 | ||
| 14-Day RSI | 77.18 | ||
| 14-Day ATR (C$) | 0.020007 | ||
| 20-Day SMA (C$) | 0.42425 | ||
| 12-1 Month Momentum % | -22.73 | ||
| 52-Week Range (C$) | 0.35 - 0.57 | ||
| Shares Outstanding (Mil) | 108.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LSL Pharma Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LSL Pharma Group Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
LSL Pharma Group Inc Frequently Asked Questions
What is LSL Pharma Group Inc(TSXV:LSL)'s stock price today?
The current price of TSXV:LSL is C$0.50. The 52 week high of TSXV:LSL is C$0.57 and 52 week low is C$0.35.
When is next earnings date of LSL Pharma Group Inc(TSXV:LSL)?
The next earnings date of LSL Pharma Group Inc(TSXV:LSL) is .
Does LSL Pharma Group Inc(TSXV:LSL) pay dividends? If so, how much?
LSL Pharma Group Inc(TSXV:LSL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers